Chapter: Anaphylaxis and Anaphylactic Shock
McMaster Section Editor(s): Judah A. Denburg
Section Editor(s) in Interna Szczeklika: Marek L. Kowalski, Agnieszka Padjas
McMaster Author(s): Paul K. Keith, Judah A. Denburg
Author(s) in Interna Szczeklika: Jerzy Kruszewski, Miłosz Jankowski
How to Cite This Chapter: Keith PK, Denburg JA, Kruszewski J, Jankowski M. Anaphylaxis and Anaphylactic Shock. McMaster Textbook of Internal Medicine. Kraków: Medycyna Praktyczna. https://empendium.com/mcmtextbook/chapter/B31.V.25.2.3.?utm_source=nieznany&utm_medium=referral&utm_campaign=social-chapter-link Accessed July 20, 2019.
Last Updated: May 19, 2015
Last Reviewed: April 7, 2016
Main Documents Taken Into Account:
Simons FE, Ardusso LR, Bilň MB, et al. International consensus on (ICON) anaphylaxis. World Allergy Organ J. 2014 May 30;7(1):9. doi: 10.1186/1939-4551-7-9. eCollection 2014. PubMed PMID: 24920969; PubMed Central PMCID: PMC4038846.
Dhami S, Panesar SS, Roberts G, et al; EAACI Food Allergy and Anaphylaxis Guidelines Group. Management of anaphylaxis: a systematic review. Allergy. 2014 Feb;69(2):168-75. doi: 10.1111/all.12318. Epub 2013 Nov 20. PubMed PMID: 24251536.
Simons FE, Ardusso LR, Dimov V, et al; World Allergy Organization. World Allergy Organization Anaphylaxis Guidelines: 2013 update of the evidence base. Int Arch Allergy Immunol. 2013;162(3):193-204. doi: 10.1159/000354543. Epub 2013 Sep 5. Review. PubMed PMID: 24008815.
Simons FE, Ardusso LR, Bilň MB, et al; World Allergy Organization. 2012 Update: World Allergy Organization Guidelines for the assessment and management of anaphylaxis. Curr Opin Allergy Clin Immunol. 2012 Aug;12(4):389-99. doi: 10.1097/ACI.0b013e328355b7e4. PubMed PMID: 22744267.
Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol. 2010 Oct;105(4):259-273. doi: 10.1016/j.anai.2010.08.002. PubMed PMID: 20934625.
Lieberman P, Nicklas RA, Oppenheimer J, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol. 2010 Sep;126(3):477-80.e1-42. PMID: 20692689
Definition, Etiology, PathogenesisTop
Anaphylaxis is a severe, life-threatening, generalized or systemic rapid-onset hypersensitivity reaction (allergic or nonallergic).
Anaphylactic shock is a severe, rapidly progressing anaphylactic reaction (anaphylaxis) resulting in a life-threatening drop in blood pressure.
The most frequent causes of anaphylaxis:
a) Drugs: Most commonly beta-lactam antibiotics, cytotoxic agents.
b) Hymenoptera venoms (see Insect Stings).
c) Proteins administered via parenteral routes, including blood and its products, enzymes (eg, streptokinase), sera (eg, tetanus immunoglobulin), allergens used for in vivo diagnosis and immunotherapy.
d) Foods: In adults most commonly fish, seafood, peanuts.
e) Inhaled allergens, for instance, animal dander.
a) Direct release of mediators from mast cells: Opioids, muscle relaxants, colloids (eg, dextran, hydroxyethyl starch, human albumin), hypertonic solutions (eg, mannitol), physical exercise.
b) Immunologic complexes: Blood and its products, immunoglobulins, animal sera, vaccines, dialysis membranes.
c) Alterations of arachidonic acid metabolism: Hypersensitivity to acetylsalicylic acid (ASA) and other nonsteroidal anti-inflammatory drugs (NSAIDs).
d) Histamine and tyramine present in foods, low activity of enzymes degrading the mediators of anaphylaxis.
e) Other mechanisms: Radiologic contrast media, food contaminants and preservatives, or unknown causes.
Nonallergic reactions are not mediated by immunologic mechanisms, and therefore shock may occur even at the first exposure to a certain factor. In ~30% of cases, the causative factor remains unknown despite a thorough diagnostic workup (idiopathic anaphylaxis). However, the most frequent mechanism of anaphylaxis is an IgE-related reaction, while nonimmune reactions are less prevalent. Their common feature is degranulation of mast cells and basophils. The released mediators, such as histamine, tryptase, arachidonic acid metabolites, platelet activating factor, or NO, cause bronchial and gastrointestinal (GI) smooth muscle contraction and vasodilation, increased vascular permeability, stimulation of sensory nerve endings, recruitment of inflammatory cells, and activation of the complement, coagulation, and fibrinolysis cascades. Increased vascular permeability and rapid fluid transfer to extravascular compartment may lead to the loss of as much as 35% of effective circulating blood volume within ~10 minutes.
Clinical Features and Natural HistoryTop
Signs and symptoms of anaphylaxis most often occur within seconds or minutes of exposure to a trigger (though in some cases they may develop later, even after several hours):
1) Skin and subcutaneous tissue: Urticaria/angioedema and erythema occur in up to 90% of cases.
2) Respiratory system: Upper airway edema, hoarseness, stridor, cough, wheezing, respiratory compromise, rhinitis.
3) GI system: Nausea, vomiting, abdominal pain, diarrhea.
4) Systemic reactions: Hypotension and other symptoms of shock occur in 30% of cases; they may occur simultaneously with other signs and symptoms of anaphylaxis or (usually) develop shortly after their onset.
5) Less frequent: Dizziness or headache, uterine cramps, anxiety, feeling of impending doom.
The more rapidly the symptoms develop, the higher the risk of severe and life-threatening anaphylaxis; however, it should be noted that symptoms which are initially mild (eg, limited to the skin and subcutaneous tissue) may also rapidly become life-threatening if an adequate treatment is not started promptly. Delayed or biphasic reactions may occur, with symptoms developing or relapsing over 8 to 12 hours. Symptoms of anaphylaxis may last for hours or even days despite adequate treatment.
Signs and symptoms of anaphylactic shock (regardless of the trigger) include cold and pale skin, sweating, collapsed subcutaneous veins, hypotension, oliguria or anuria, loss of bowel control, and loss of consciousness. Circulatory arrest may occur.
According to the 2011 World Allergy Organization Guidelines, anaphylaxis is highly likely when any of the following criteria is fulfilled:
1) Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal tissue, or both (eg, urticaria, itching, lips-tongue-uvula edema), which is accompanied by either (or both):
a) Respiratory compromise (eg, dyspnea, stridor, wheeze-bronchospasm, hypoxemia).
b) Reduced blood pressure or associated symptoms of end-organ dysfunction (eg, hypotonia, syncope, incontinence).
2) Exposure to a likely allergen for a patient is rapidly (within minutes to several hours) followed by ≥2 of the following:
a) Involvement of the skin-mucosal tissue (eg, urticaria, itching, lips-tongue-uvula edema).
b) Respiratory compromise (eg, dyspnea, stridor, wheeze-bronchospasm, hypoxemia).
c) Reduced blood pressure or associated symptoms (eg, hypotonia, syncope, incontinence).
d) Persistent GI symptoms (crampy abdominal pain, vomiting).
3) Decreased blood pressure following exposure to a “known allergen” (within minutes to several hours):
a) Infants and children: A low systolic pressure (age-related) or decrease >30% in systolic blood pressure. (In children, a low systolic blood pressure is defined as <70 mm Hg from 1 month to 1 year; <[70 mm Hg + 2 x age] from 1 to 10 years; and <90 mm Hg from 11 to 17 years.)
b) Adults: A systolic blood pressure <90 mm Hg or >30% compared to the patient’s baseline.
Infants are more likely to have respiratory compromise than hypotension or shock, and in this age group, shock is more likely to be manifested initially by tachycardia than by hypotension.
1. Assays measuring the levels of tryptase, histamine, or methylhistamine are not widely available, not specific for anaphylaxis, and not routinely used.
2. Where there is a clear causative agent, it is best to simply avoid exposure rather than confirm the cause by performing a challenge test. Often sensitivity may be lost over time, and where alternative agents cannot be used, cautious challenge under close observation and after a full discussion with the patient could be considered. Such an attempt to establish the allergic cause of anaphylaxis with skin tests should be made, if considered essential, no earlier than 3 to 4 weeks after the episode. Generally, challenge tests are not recommended after anaphylactic shock. Assessing the levels of IgE specific to suspected allergens may be helpful.
1. Assess airway, breathing, circulation, and level of consciousness. Establish and maintain the airway if necessary, and in case of respiratory or cardiac arrest, start cardiopulmonary resuscitation (see Cardiac Arrest). In patients with stridor or significant edema of the face and upper airways (tongue, oral and throat mucosa, hoarseness), consider immediate endotracheal intubation. If delayed, it may be progressively more difficult, and unsuccessful intubation attempts may further aggravate the edema. If the edema causes life-threatening airway obstruction and attempts of endotracheal intubation have been unsuccessful, perform cricothyroidotomy (see Percutaneous Cricothyrotomy).
2. Stop the exposure to the suspected antigen (eg, stop the infusion of a drug or blood transfusion).
3. Administer epinephrine as soon as possible once anaphylaxis is recognized:
1) In patients with a history of anaphylaxis who carry an epinephrine autoinjector, immediately administer 1 IM dose of epinephrine in the lateral thigh in case of even minor symptoms suggestive of anaphylaxis.
2) In patients without cardiac arrest, administer IM epinephrine in the lateral thigh in a dose 0.01 mg/kg of a 1:1000 (1 mg/mL) solution to a maximum of 0.5 mg in adults (0.3 mg in children).
Record the time of injection and repeat in 5 to 15 minutes as necessary. Most patients respond to 1 to 2 doses. Patients who do not respond to an intramuscular injection of epinephrine and fluid resuscitation (shock is imminent or has already developed) should receive epinephrine in a slow intravenous infusion; the dose should be titrated on the basis of the effect of treatment on blood pressures assessed using continuous noninvasive monitoring. In adults, the starting dose is 2 to 10 microg/min in an intravenous infusion (0.1 mg/mL, 1:10,000 solution contains 100 microg/mL or 1000 microg in a 10 mL syringe).
4. Place the patient on the back, or in a different position of comfort and safety if there is respiratory distress and/or vomiting, and elevate the lower extremities, as this may be helpful in the management of hypotension. Do not let the patient sit or stand up suddenly or be placed in an upright position.
5. Administer oxygen 6 to 8 L/min via a face mask. This is indicated in patients in whom it was necessary to administer several doses of epinephrine, patients with respiratory distress, signs and symptoms of myocardial ischemia, or chronic diseases of the respiratory system.
6. Establish peripheral intravenous access with 2 large-bore needles (optimally ≥1.6-1.8 mm [14-16 gauge]) and use infusion kits allowing for rapid fluid administration.
7. Administer intravenous fluids: In patients with a substantial decrease in blood pressure who do not respond to intramuscular epinephrine, administer a rapid intravenous infusion of 1 to 2 L of isotonic crystalloid (eg, in adults, 5-10 mL/kg of 0.9% saline over the first 5 to 10 minutes [10 mL/kg in children]).
8. Monitor blood pressure and, depending on the clinical situation, also electrocardiography (ECG), SpO2, or arterial blood gases.
1. In patients receiving beta-blockers who do not respond to epinephrine, consider intravenous administration of glucagon 1 to 5 mg in a slow infusion over ~5 minutes and then in a continuous IV infusion 5 to 15 microg/min, depending on the clinical response. Nausea, vomiting, and hyperglycemia are frequent adverse effects.
2. Intravenous H1 antihistamines are recommended in case of itching, urticaria, angioedema, nasal and ocular symptoms (diphenhydramine 25-50 mg IV [1 mg/kg; max 50 mg in children]). H1-receptor blockers do not prevent or relieve upper airway obstruction, hypotension, or shock, and they should never be substituted for epinephrine.Evidence 1 Strong recommendation (benefits clearly outweigh downsides; right action for all or almost all patients). Low Quality of Evidence (low confidence that we know true effects of the intervention). Quality of Evidence lowered due to the lack of direct experimental data in humans. At the same time, this treatment is routinely used based on the use of this class of drugs in less severe allergic conditions and we recommend it unless better data become available. Sheikh A, ten Broek Vm, Brown SG, Simons FE. H1-antihistamines for the treatment of anaphylaxis with and without shock. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD006160. Review. PubMed PMID: 17253584.
3. Consider IV H2 antagonist in cases of hypotension: ranitidine 50 mg every 8 to 12 hours or 150 mg orally bid.[EVIDENCE #2; y/L]
4. Give an IV glucocorticoid,Evidence 3 Strong recommendation (benefits clearly outweigh downsides; right action for all or almost all patients). Moderate Quality of Evidence (moderate confidence that we know true effects of the intervention). Quality of Evidence lowered due to only indirect evidence from other acute allergic conditions (acute asthma) and no direct experimental data available in humans. Consequently, the dose is not clear. Choo KJ, Simons FE, Sheikh A. Glucocorticoids for the treatment of anaphylaxis. Cochrane Database Syst Rev. 2012 Apr 18;4:CD007596. doi: 10.1002/14651858.CD007596.pub3. Review. PubMed PMID: 22513951. Smith M, Iqbal S, Elliott TM, Everard M, Rowe BH. Corticosteroids for hospitalised children with acute asthma. Cochrane Database Syst Rev. 2003;(2):CD002886. Review. PubMed PMID: 12804441. Rowe BH, Spooner C, Ducharme FM, Bretzlaff JA, Bota GW. Early emergency department treatment of acute asthma with systemic corticosteroids. Cochrane Database Syst Rev. 2001;(1):CD002178. Review. PubMed PMID: 11279756 eg, methylprednisolone 1 to 2 mg/kg, then 1 mg/kg/d, or hydrocortisone 200 to 400 mg, then 100 mg every 6 hours, for a maximum of 3 days; although this is not effective in treatment of the acute phase of anaphylactic shock, it may prevent the late phase of anaphylaxis. As in asthma, if there is wheezing, glucocorticoids may potentiate the beta-agonist receptors. In the case of anaphylaxis without signs and symptoms of shock, airway edema, or respiratory compromise, an oral glucocorticoid, eg, prednisone 0.5 mg/kg/d, may be used.
5. Inhaled bronchodilators should be used if wheezing, coughing, and shortness of breath are not relieved by epinephrine; preferably use nebulized albuterol (INN salbutamol) 2.5 or 5 mg in 3 mL 0.9% saline or 2 to 4 puffs with an Aerochamber if the patient is able to follow instructions. The inhalation may be repeated when necessary. Bronchodilators reduce airway obstruction but do not prevent or relieve laryngeal symptoms, hypotension, or shock and should never be used instead of epinephrine.
6. Admit the patient to an intensive care unit without delay if anaphylaxis is refractory to treatment.
Follow-up after the resolution of signs and symptoms of anaphylaxis:
1) Monitor the patients for 8 to 24 hours for a possible late-phase reaction or protracted anaphylaxis. Extend the monitoring to 24 hours in patients with severe anaphylaxis of unknown etiology, slow onset of symptoms, severe asthma, or severe bronchospasm, or if continued exposure to the triggering allergen is probable, as well as in patients with a history of biphasic anaphylactic reactions.
2) Patients in whom the symptoms of anaphylaxis do not recur within 8 hours of the completed treatment may be discharged. They should be advised of the possibility of recurrent symptoms and instructed how to act in such cases. Patients should receive a prescription for epinephrine autoinjector, written anaphylaxis emergency action plan, and medical identification (bracelet, necklace) indicating that they have experienced anaphylaxis and specifying the responsible agent (if known). Educate the patient and his or her family or caregivers on the usage of epinephrine autoinjector and the emergency action plan.
3) Refer the patient to an allergy specialist to confirm the diagnosis and suspected triggers and to plan the prevention and further management (see below).
In patients with a history of suspected anaphylaxis or an episode diagnosed as anaphylaxis, establish whether it was actually anaphylaxis and whether the suspected trigger was a true trigger of the reaction. The investigations of the putative trigger should be performed not earlier than 3 to 4 weeks after the episode. An algorithm of the initial evaluation and management in patients with a history of suspected anaphylaxis: Figure. Algorithm of initial evaluation and….
1. Measures used to reduce the risk of anaphylactic shock:
1) Administration of drugs: If possible, administer drugs orally rather than parenterally. Always ask about allergies when taking history, particularly prior to intravenous drug administration. Never ignore notes added by other physicians or the patients’ opinion on drug hypersensitivity. Follow the recommended testing for hypersensitivity and administration of the drug that may trigger anaphylaxis. If the drug is administered intramuscularly or subcutaneously, make sure that the needle has not been introduced into a blood vessel. Monitor the patient for 30 to 60 minutes after the administration of a drug that may potentially induce anaphylaxis.
2) Administration of vaccines or sera:
a) Antiviral vaccines: Take the history on hypersensitivity to egg proteins.
b) Antitoxins (eg, tetanus, diphtheria, or botulinum toxoids, or snake venom serum): Administer human serum. If human serum is not available and allergy to animal serum is suspected, administer both H1-receptor and H2-receptor blockers and an oral or intravenous glucocorticoid prior to the administration of the serum.
3) Allergy diagnostic testing: Whenever possible, skin prick tests should be performed before proceeding to intradermal tests. Since intradermal tests are about 1000 times as potent as skin prick tests, if the skin prick test is negative, use a 1:100 dilution of the reagent used for skin prick testing to perform an intradermal test that is then 10 times as potent as the skin prick test. Intradermal tests are used for diagnosis of anaphylaxis to venoms and drugs such as penicillin. For pollen-allergic patients, skin prick tests are usually sensitive enough and can be performed at any time. Challenge tests with drugs, either oral or bronchial, should be performed in an inpatient or outpatient setting with emergency medications and equipment to promptly treat anaphylaxis under direct medical supervision by a clinician with an appropriate training and an immediate access to supportive care, if needed.
4) Allergy testing postanaphylaxis: see above.
2. Medical procedures associated with an increased risk of anaphylaxis (eg, specific allergen immunotherapy, intravenous administration of biological drugs, or contrast media):
1) Equipment and drugs: A stethoscope, a blood pressure measurement device; tourniquets, syringes, hypodermic needles, large-bore needles (14 gauge or 16 gauge); injectable epinephrine (1 mg/mL); equipment for oxygen therapy; airway masks and a self-inflating (Ambu) ventilation bag with facial mask; 0.9% saline (at least 500 mL bottles or bags) and intravenous transfusion kits; intravenous antihistamines both H1 antagonists and H2 antagonists (eg, diphenhydramine and ranitidine); intravenous glucocorticoids (eg, methylprednisolone, hydrocortisone); a nebulizer and inhaled short-acting beta-agonist (eg, salbutamol);
2) The risk associated with the administration of an allergen, drug, or diagnostic agent may be reduced by previous oral or intravenous administration of H1-receptor and H2-receptor blockers (eg, diphenhydramine and ranitidine) and/or a glucocorticoid (eg, prednisone 0.5 mg/kg orally 3 times: 12, 7, and 1 hour before the administration of a drug or diagnostic agent that may induce anaphylaxis).
Secondary prevention refers to prevention methods in patients with a history of anaphylactic shock. Adequate use of prophylactic measures requires an appropriate education of patients.
1. Avoidance of triggers, if identified.
2. Carrying an epinephrine autoinjector at all times.
3. Carrying a relevant medical identification bracelet, necklace, or card.
4. Pharmacologic prophylaxis: Long-term antihistamine treatment in patients with idiopathic anaphylaxis, or prophylactic administration of H1 antihistamines and H2 antihistamines and/or a glucocorticoid prior to an expected exposure to the trigger (eg, before contrast-enhanced imaging [see above]). This is not effective in exercise-induced anaphylaxis.
5. Specific allergen immunotherapy, if possible (eg, specific immunotherapy in patients with an allergy to hymenoptera venom or specific immunotherapy for a drug allergy), or immune tolerance induction (in patients with hypersensitivity to drugs, eg, chemotherapeutic agents, monoclonal antibodies, antibiotics, ASA).
1) Oral desensitization to a specific food, such as milk, eggs, or peanuts, can be achieved in carefully selected patients monitored by physicians.Evidence 4 Weak recommendation (benefits likely outweigh downsides, but the balance is close or uncertain; an alternative course of action may be better for some patients). High Quality of Evidence (high confidence that we know true effects of the intervention). Jones SM, Pons L, Roberts JL, et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol. 2009 Aug;124(2):292-300, 300.e1-97. doi: 10.1016/j.jaci.2009.05.022. Epub 2009 Jul 3. PubMed PMID: 19577283; PubMed Central PMCID: PMC2725434. Hofmann AM, Scurlock AM, Jones SM, et al. Safety of a peanut oral immunotherapy protocol in children with peanut allergy. J Allergy Clin Immunol. 2009 Aug;124(2):286-91, 291.e1-6. doi: 10.1016/j.jaci.2009.03.045. Epub 2009 May 27. PubMed PMID: 19477496; PubMed Central PMCID: PMC2731305. Adverse effects, sometimes requiring the administration of epinephrine, occur during oral desensitization, especially during the initial dose escalation.
2) An anti-IgE antibody given subcutaneously can increase the margin of protection against inadvertently ingested foods (and other allergens) for patients at risk of anaphylaxis.Evidence 5 Weak recommendation (benefits likely outweigh downsides, but the balance is close or uncertain; an alternative course of action may be better for some patients). Moderate Quality of Evidence (moderate confidence that we know true effects of the intervention). Quality of Evidence lowered due to indirectness of outcome measures. An anti-IgE antibody given subcutaneously can increase the margin of protection against inadvertently ingested foods (and other allergens) for patients at risk of anaphylaxis, although it is not a cure. Leung DY, Sampson HA, Yunginger JW, et al; Avon Longitudinal Study of Parents and Children Study Team. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med. 2003 Mar 13;348(11):986-93. Epub 2003 Mar 10. PubMed PMID: 12637608. This is still an experimental strategy.
3) For anaphylaxis triggered by a medication, if it is not possible to substitute an alternative drug, physician-supervised desensitization strategies with the offending agent are effective and safe, particularly for beta-lactam or other antibiotics, aspirin, other NSAIDs, and chemotherapy agents.Evidence 6 Strong recommendation (benefits clearly outweigh downsides; right action for all or almost all patients). Moderate Quality of Evidence (moderate confidence that we know true effects of the intervention). Quality of Evidence lowered due to the observational nature of data, but results are consistent and therefore confidence was increased to moderate. Celik W, Pichler WJ, Adkinson NF Jr. Drug allergy. In: Adkinson NF Jr., Bochner BS, Busse WW, Holgate ST, Lemanske RF Jr., Simons FER, eds. Middleton’s Allergy: Principles and Practice. 7th ed. St Louis: Mosby, Inc.; 2009: 1205-26. Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol. 2008 Sep;122(3):574-80. doi: 10.1016/j.jaci.2008.02.044. Epub 2008 May 27. PubMed PMID: 18502492. Mirakian R, Leech SC, Krishna MT, et al; Standards of Care Committee of the British Society for Allergy and Clinical Immunology. Management of allergy to penicillins and other beta-lactams. Clin Exp Allergy. 2015 Feb;45(2):300-27. doi: 10.1111/cea.12468. PubMed PMID: 25623506. Lee RU, White AA, Ding D, et al. Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2010 Aug;105(2):130-5. doi: 10.1016/j.anai.2010.05.020. Epub 2010 Jul 1. PubMed PMID: 20674823. Wong JT, Nagy CS, Krinzman SJ, Maclean JA, Bloch KJ. Rapid oral challenge-desensitization for patients with aspirin-related urticaria-angioedema. J Allergy Clin Immunol. 2000 May;105(5):997-1001. PubMed PMID: 10808182. Desensitization lasts as long as the medication is regularly administered; however, immunologic tolerance does not occur, and if the medication is discontinued for a time, symptoms recur when it is restarted.
4) Stinging insect venom anaphylaxis can be prevented by desensitization in most patients who receive a 3- to 5-year course of subcutaneous immunotherapy to the relevant venoms.Evidence 7 Strong recommendation (benefits clearly outweigh downsides; right action for all or almost all patients). High Quality of Evidence (high confidence that we know true effects of the intervention). Freeman TM. Clinical practice. Hypersensitivity to hymenoptera stings. N Engl J Med. 2004 Nov 4;351(19):1978-84. Review. PubMed PMID: 15525723. Golden DB. Insect sting allergy and venom immunotherapy: a model and a mystery. J Allergy Clin Immunol. 2005 Mar;115(3):439-47; quiz 448. Erratum in: J Allergy Clin Immunol. 2005 Jun;115(6):1128. PubMed PMID: 15753884.
All these measures must be accompanied by an appropriate patient education.